PharmCAT.NET

Биостатистика, фармакокинетика и клинические исследования.

  • Домашняя страница
    • О сайте
  • Материалы
    • Быстрые команды R Project
    • Ссылки
  • Инструменты
    • Рандомизационный список
  • Блог
    • Статистика
    • Phoenix WinNonlin
    • IT
    • Путевые заметки
  • Контакты
    • Контактные данные
    • Консультации
    • Конфиденциальность
  • Профиль
    • Войти
    • Зарегистрироваться

Adaptive Designs for Clinical Trials of Drugs and Biologics Guidance for Industry – FDA

Опубликовано 3 октября, 201817 декабря, 2018 frozencat

Обновление руководства FDA:

Adaptive Designs for Clinical Trials of Drugs and Biologics Guidance for Industry

Руководство замещает Adaptive Design Clinical Trials for Drugs and Biologics – 2010.

Рубрики: Блог

Навигация по записям

Предыдущая запись: Определение объема выборки для исследований биоэквивалентности с использованием компьютерного моделирования
Следующая запись: Работа с данными в IBM SPSS: присвоение меток переменным из другого источника

Свежие записи

  • Long WS Wide: или про то, как выполнить анализ разницы изменений между группами
  • Частые вопросы: Регистрация и экспертиза по правилам ЕАЭС
  • Главные ошибки при формировании базы данных в MS Excel
  • Тест ClinicalTrialUtilities и ReplicateBE на Raspberry Pi 4
  • Julia:ReplicateBE – release 0.2.0

Галерея

20180812 001405
20170731 132822
IMG-20170802-WA0015
IMG-20170807-WA0031
IMG-20170807-WA0038
IMG-20170806-WA0015
  • OTP Events, Meetings, and Workshops
    Source: FDA - What's New: Vaccines, Blood & Biologics RSS Feed Published on 2025-10-29 By FDA
  • Human medicines European public assessment report (EPAR): Brukinsa, zanubrutinib, Date of authorisation: 22/11/2021, Revision: 14, Status: Authorised
    Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2025-10-29
  • Human medicines European public assessment report (EPAR): Fabhalta, iptacopan, Date of authorisation: 17/05/2024, Revision: 5, Status: Authorised
    Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2025-10-29
  • Human medicines European public assessment report (EPAR): Lytgobi, futibatinib, Date of authorisation: 04/07/2023, Revision: 3, Status: Authorised
    Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2025-10-29
  • TECARTUS
    Source: FDA - What's New: Vaccines, Blood & Biologics RSS Feed Published on 2025-10-29 By FDA
  • Human medicines European public assessment report (EPAR): Lynparza, olaparib, Date of authorisation: 16/12/2014, Revision: 29, Status: Authorised
    Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2025-10-29
  • Human medicines European public assessment report (EPAR): Rybrevant, amivantamab, Date of authorisation: 09/12/2021, Revision: 10, Status: Authorised
    Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2025-10-29
  • Biosimilars Guidances
    Source: FDA - What's New: Drugs RSS Feed Published on 2025-10-29 By FDA
  • Scientific Considerations in Demonstrating Biosimilarity to a Reference Product: Updated Recommendations for Assessing the Need for Comparative Efficacy Studies
    Source: FDA - What's New: Drugs RSS Feed Published on 2025-10-29 By FDA
  • CANCELED - 17th Annual Sentinel Initiative Public Workshop - 11/06/2025
    Source: FDA - What's New: Drugs RSS Feed Published on 2025-10-29 By FDA
  • Roster of the Cellular, Tissue and Gene Therapies Advisory Committee
    Source: FDA - What's New: Vaccines, Blood & Biologics RSS Feed Published on 2025-10-29 By FDA
  • POSTPONED - 17th Annual Sentinel Initiative Public Workshop - 11/06/2025
    Source: FDA - What's New: Drugs RSS Feed Published on 2025-10-29 By FDA
  • Roster of the Blood Products Advisory Committee
    Source: FDA - What's New: Vaccines, Blood & Biologics RSS Feed Published on 2025-10-28 By FDA
  • GDUFA III Reauthorization
    Source: FDA - What's New: Drugs RSS Feed Published on 2025-10-28 By FDA
  • Human medicines European public assessment report (EPAR): Cabometyx, cabozantinib, Date of authorisation: 09/09/2016, Revision: 20, Status: Authorised
    Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2025-10-28
Предыдущие записи
Тема: Scaffold от Danny Cooper.